Real-world effectiveness and safety of Ocrelizumab in a gulf multiple sclerosis cohort: extension of the Q-OCRE study to 451 patients
Multiple Sclerosis and Related Disorders · 2026-11 · 115 · 107971
DOI: 10.1016/j.msard.2026.107971 ↗Kurz gefasst
Fachartikel in der Zeitschrift Multiple Sclerosis and Related Disorders, 2026-11. Verfasst von Khaled Zammar und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Neuroscience Institute, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar; Weill Cornell Medicine-Qatar, Doha, …. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Immunologic Factors, Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Relapsing-Remitting. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Real-world evidence on ocrelizumab in multiple sclerosis (MS) from the Middle East and North Africa (MENA) is limited. We extended our original Q-OCRE cohort (n = 60) to evaluate effectiveness and safety in an ethnically diverse Gulf population. In a single-center retrospective cohort of all patients starting ocrelizumab at Hamad General Hospital, Doha, Qatar (October 2017-May 2025), the primary outcome was No Evidence of Disease Activity (NEDA-3) at Year 1; secondary outcomes were annualized relapse rate (ARR), Expanded Disability Status Scale (EDSS) trajectory, 24-week confirmed disability worsening (CDW), persistence, and safety. A total of 451 patients were included (86.7% RRMS, 7.1% SPMS, 6.2% PPMS; 57.6% female; mean age 34.3 years; median follow-up 18.1 months; 696 person-years). The cohort was mildly affected at initiation (median EDSS 1.0; 42% with no relapse in the prior 2 years). ARR fell from 0.381 to 0.046, an 87% reduction (IRR 0.13, 95% CI 0.07-0.22, p < 0.001), preserved in patients meeting trial-like activity criteria (IRR 0.09). The EDSS slope was -0.04 points/year (p = 0.03) with a phenotype-by-time interaction (p < 0.001): RRMS improved while progressive forms worsened. NEDA-3 was 59.0% at Year 1 and 61.7% at Year 2. 24-week CDW reached 8.9% at 36 months, progressive phenotype being the only independent predictor (HR 5.02). Persistence was 90.7% at 36 months. Infusion-related reactions occurred in 18.4%, adjudicated opportunistic infections in 1.0%, IgG below 7 g/L in 6.9%, and incident malignancy in 0.4%, with no deaths and no progressive multifocal leukoencephalopathy. Ocrelizumab showed robust effectiveness and a favorable safety profile in this Gulf cohort, with disability trajectories dissociating by phenotype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Neuroscience Institute, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar; Weill Cornell Medicine-Qatar, Doha, Qatar; College of Medicine, Qatar University, Doha, Qatar. Electronic…
- Department of Neurology, Neuroscience Institute, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
- Department of Neurology, Neuroscience Institute, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar; Weill Cornell Medicine-Qatar, Doha, Qatar.
Zitieren
APA
Zammar, K., Abualrob, M. A., Yasin, R., Althani, A., Alemadi, A., Hassanein, D., Alshehab, S., Baniamer, Y., Eltazi, I., Sayed Abdelmoneim, M., Ahmed, F., Mallat, F., Khodair, R., Hamid, S., & Garcia-Cañibano, B. (2026). Real-world effectiveness and safety of Ocrelizumab in a gulf multiple sclerosis cohort: extension of the Q-OCRE study to 451 patients. Multiple Sclerosis and Related Disorders, 115, 107971. https://doi.org/10.1016/j.msard.2026.107971
Vancouver
Zammar K, Abualrob MA, Yasin R, Althani A, Alemadi A, Hassanein D, et al. Real-world effectiveness and safety of Ocrelizumab in a gulf multiple sclerosis cohort: extension of the Q-OCRE study to 451 patients. Multiple Sclerosis and Related Disorders. 2026;115:107971. doi:10.1016/j.msard.2026.107971
BibTeX
@article{Zammar2026,
author = {Zammar, Khaled and Abualrob, Majd A and Yasin, Randa and Althani, Abdullah and Alemadi, Alghalya and Hassanein, Doaa and Alshehab, Sami and Baniamer, Yahya and Eltazi, Isra and Sayed Abdelmoneim, Mohamed and Ahmed, Fayza and Mallat, Fatme and Khodair, Rola and Hamid, Shahd and Garcia-Cañibano, Beatriz},
title = {Real-world effectiveness and safety of Ocrelizumab in a gulf multiple sclerosis cohort: extension of the Q-OCRE study to 451 patients},
journal = {Multiple Sclerosis and Related Disorders},
year = {2026},
volume = {115},
pages = {107971},
doi = {10.1016/j.msard.2026.107971}
}
EUVIMED